Cellosaurus cell line ADK-VR2 AG143 (CVCL

Cellosaurus ADK-VR2 AG143 (CVCL_E6J6)

Entry history
Cell line name	ADK-VR2 AG143
Accession	CVCL_E6J6
Resource Identification Initiative	To cite this cell line use: ADK-VR2 AG143 (RRID:CVCL_E6J6)
Comments	Population: Southeast Asian; Filipino. Characteristics: Grown in 3D culture in the presence of crizotinib. Has a significantly lower sensitivity to crizotinib than the parental cell line in adherent cultures and is not sensitive to lorlatinib, entrectinib and DS-6051b (PubMed=36519016). Doubling time: 25.77 hours (Direct_author_submission). Selected for resistance to: ChEBI; CHEBI_64310; Crizotinib (Xalkori). Donor information: Established from a treatment-naive non-smoker patient (PubMed=36519016). Miscellaneous: Doubling time and ethnic origin of patient from personal communication of Angelicola, Stefania. Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations	Gene fusion; HGNC; HGNC:10261; ROS1 + HGNC; HGNC:10661; SDC4; Name(s)=SDC4-ROS1; Note=SDC4 exon 2 fused to ROS exon 32 (PubMed=36519016).
Disease	Lung adenocarcinoma (NCIt: C3512)
Species of origin	Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy	Parent: CVCL_E6J5 (ADK-VR2)
Sex of cell	Male
Age at sampling	46Y
Category	Cancer cell line
Publications	PubMed=36519016; DOI=10.21037/tlcr-22-163; PMCID=PMC9742620 Ruzzi F., Angelicola S., Landuzzi L., Nironi E., Semprini M.S., Scalambra L., Altimari A., Gruppioni E., Fiorentino M., Giunchi F., Ferracin M., Astolfi A., Indio V., Ardizzoni A., Gelsomino F., Nanni P., Lollini P.-L., Palladini A. ADK-VR2, a cell line derived from a treatment-naive patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC. Transl. Lung Cancer Res. 11:2216-2229(2022)
Entry creation	10-Apr-2025
Last entry update	10-Apr-2025
Version number	1